Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GILEAD SCIENCES, INC.GILD · Entity 405 | Director | February 06, 2019 | February 08, 2019 |
| Kronos Bio, Inc.KRON · Entity 78257 | Director | October 14, 2020 | October 16, 2020 |
| Sarepta Therapeutics, Inc.SRPT · Entity 4426 | Director | March 03, 2021 | March 06, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GILEAD SCIENCES, INC.
Report date February 06, 2019 · Filed February 08, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 2,887,225 |
Ending reported balance
After 2019-02-06 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2019-02-06 · Grant · Acquired 7,745 · Balance 2,885,507 F1: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 2 · 2019-02-06 · Grant · Acquired 15,505 · Balance 2,901,012 F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. Row 3 · 2019-02-06 · Tax withholding · Disposed 13,787 · Balance 2,887,225 |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of the Issuer's common stock subject to specific tranches of the performance share awards made to the Reporting Person on February 2, 2017. Such tranches of shares were subject to both performance-vesting and service-vesting requirements. The performance vesting requirement was satisfied on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors. However, the shares will not be issued to the Reporting Person until such individual upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
F2: Represents shares of the Issuer's common stock subject to specific tranches of the performance share award made to the Reporting Person on February 1, 2016. Such tranches of shares were subject to performance-vesting and service-vesting requirements and became issuable on the date reported in Column 2 above upon certification of performance goal attainment by the Compensation Committee of the Issuer's Board of Directors.
Kronos Bio, Inc.
Report date October 14, 2020 · Filed October 16, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectSee footnote | 1,952,364 |
Last balance in matching sequence
After 2020-10-14 transaction · row 4
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
4 source rowsRow 1 · 2020-10-14 · Conversion · Acquired 914,333 · Balance 914,333 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 2 · 2020-10-14 · Conversion · Acquired 756,971 · Balance 1,671,304 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 3 · 2020-10-14 · Conversion · Acquired 205,260 · Balance 1,876,564 F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. Row 4 · 2020-10-14 · Purchase · Acquired 75,800 · Balance 1,952,364 F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Series Seed Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-10-14 · Conversion · Disposed 866,667 · Balance 0 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Series A Preferred StockSEC Table II · derivative / convertible security | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-10-14 · Conversion · Disposed 717,509 · Balance 0 F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
| Convertible Promissory NoteSEC Table II · derivative / convertible security · Conversion / exercise price $16.15 · Expires 2022-02-20 | IndirectSee footnote | 0 |
Reported balance
After 2020-10-14 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-10-14 · Conversion · Disposed Not disclosed · Balance 0 F3: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering. F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series Seed Preferred Stock and Series A Preferred Stock (the "Preferred Stock") automatically converted into 1.055 shares of Common Stock upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
F2: The securities are held by Nexus Development PA, LLC ("Nexus"). Dr. Martin currently serves as the President of Nexus. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
F3: The convertible promissory note automatically converted into shares of the Issuer's common stock upon the closing of the Issuer's initial public offering.
Sarepta Therapeutics, Inc.
Report date March 03, 2021 · Filed March 06, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,913 |
Reported balance
After 2021-03-03 transaction · row 1
1 source rowRow 1 · 2021-03-03 · Grant · Acquired 2,726 · Balance 7,913 F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $87.11 · Expires 2031-03-03 | Direct | 5,518 |
Reported balance
After 2021-03-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-03-03 · Grant · Acquired 5,518 · Balance 5,518 |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock. The RSUs will vest in full on March 3, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 06, 2004 Filed Feb 9, 2004 21:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $56.55 | $565,500.00 |
DisclosureSEC source: 0001179110-04-002849 · edgar.xml · nonDerivative · entry 5 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,790 Read SEC document |
| February 06, 2004 Filed Feb 9, 2004 21:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $56.51 | $565,100.00 |
DisclosureSEC source: 0001179110-04-002849 · edgar.xml · nonDerivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,790 Read SEC document |
| February 06, 2004 Filed Feb 9, 2004 21:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 50,000 | $5.63 | $281,250.00 |
DisclosureSEC source: 0001179110-04-002849 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 385,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 06, 2004 Filed Feb 9, 2004 21:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 10,000 | $6.53 | $65,313.00 |
DisclosureSEC source: 0001179110-04-002849 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 05, 2004 Filed Feb 9, 2004 21:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $56.60 | $566,000.00 |
DisclosureSEC source: 0001179110-04-002849 · edgar.xml · nonDerivative · entry 6 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345,790 Read SEC document |
| February 05, 2004 Filed Feb 9, 2004 21:52 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $56.49 | $564,900.00 |
DisclosureSEC source: 0001179110-04-002849 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 375,790 Read SEC document |
| January 28, 2004 Filed Jan 30, 2004 23:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantNon-Qualified Stock Option (right to buy) · Derivative | 423,363 | $0.00 Strike: $61.06 | $0.00 |
DisclosureSEC source: 0001179110-04-002101 · edgar.xml · derivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 423,363 Underlying: Common Stock · 423,363 shares Expires 2014-01-28 F1 · derivative.exercise_date: Options (split between incentive and non qualified stock options) vest 20% on the first anniversary date of the grant, and the remaining balance will vest quarterly over a four year period beginning on 1/28/05. The option will be fully vested by 1/28/09. Read SEC document |
| January 28, 2004 Filed Jan 30, 2004 23:04 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | GrantIncentive Stock Option (right to buy) · Derivative | 1,637 | $0.00 Strike: $61.06 | $0.00 |
DisclosureSEC source: 0001179110-04-002101 · edgar.xml · derivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,637 Underlying: Common Stock · 1,637 shares Expires 2014-01-28 F1 · derivative.exercise_date: Options (split between incentive and non qualified stock options) vest 20% on the first anniversary date of the grant, and the remaining balance will vest quarterly over a four year period beginning on 1/28/05. The option will be fully vested by 1/28/09. Read SEC document |
| December 24, 2003 Filed Dec 29, 2003 23:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionIncentive Stock Option (right to buy) · Derivative | 15,000 | Not disclosed Strike: $6.53 | Not disclosed |
DisclosureSEC source: 0001179110-03-013484 · edgar.xml · derivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,820 Underlying: Common Stock · 15,000 shares Expires 2007-07-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: stock option F1 · derivative.exercise_date: stock option Read SEC document |
| December 24, 2003 Filed Dec 29, 2003 23:06 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 15,000 | $6.53 | $97,969.50 |
DisclosureSEC source: 0001179110-03-013484 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: All shares and dollar amounts reflect two-for-one stock splits in February 2001 and March 2002. Read SEC document |
| November 04, 2003 Filed Nov 6, 2003 17:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 40,000 | $0.00 Strike: $5.63 | $0.00 |
DisclosureSEC source: 0001179110-03-010219 · edgar.xml · derivative · entry 11 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 40,000 shares Expires 2005-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Options vest in equal annual installments over five years, beginning on the first anniversary date of the grant (October 17, 1996). Read SEC document |
| November 04, 2003 Filed Nov 6, 2003 17:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 10,000 | $54.82 | $548,200.00 |
DisclosureSEC source: 0001179110-03-010219 · edgar.xml · nonDerivative · entry 10 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,790 F1 · balance_after: All shares and dollar amounts reflect two-for-one splits in February 2001 and March 2002. Read SEC document |
| November 04, 2003 Filed Nov 6, 2003 17:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,500 | $55.11 | $137,769.75 |
DisclosureSEC source: 0001179110-03-010219 · edgar.xml · nonDerivative · entry 9 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,790 Read SEC document |
| November 04, 2003 Filed Nov 6, 2003 17:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $54.77 | $273,850.00 |
DisclosureSEC source: 0001179110-03-010219 · edgar.xml · nonDerivative · entry 8 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 323,290 Read SEC document |
| November 04, 2003 Filed Nov 6, 2003 17:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,500 | $54.65 | $136,625.00 |
DisclosureSEC source: 0001179110-03-010219 · edgar.xml · nonDerivative · entry 7 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 328,290 Read SEC document |
| November 04, 2003 Filed Nov 6, 2003 17:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $54.56 | $163,680.00 |
DisclosureSEC source: 0001179110-03-010219 · edgar.xml · nonDerivative · entry 6 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,790 Read SEC document |
| November 04, 2003 Filed Nov 6, 2003 17:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $55.22 | $165,660.00 |
DisclosureSEC source: 0001179110-03-010219 · edgar.xml · nonDerivative · entry 5 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,790 Read SEC document |
| November 04, 2003 Filed Nov 6, 2003 17:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 3,000 | $55.40 | $166,200.00 |
DisclosureSEC source: 0001179110-03-010219 · edgar.xml · nonDerivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,790 Read SEC document |
| November 04, 2003 Filed Nov 6, 2003 17:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $55.09 | $275,450.00 |
DisclosureSEC source: 0001179110-03-010219 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 339,790 Read SEC document |
| November 04, 2003 Filed Nov 6, 2003 17:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 6,000 | $55.41 | $332,460.00 |
DisclosureSEC source: 0001179110-03-010219 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 344,790 Read SEC document |
| November 04, 2003 Filed Nov 6, 2003 17:18 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 40,000 | $5.63 | $225,000.00 |
DisclosureSEC source: 0001179110-03-010219 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 350,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2003 Filed Aug 12, 2003 20:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.63 | $0.00 |
DisclosureSEC source: 0001179110-03-005442 · edgar.xml · derivative · entry 9 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,000 Underlying: Common Stock · 30,000 shares Expires 2005-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2003 Filed Aug 12, 2003 20:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.50 | $0.00 |
DisclosureSEC source: 0001179110-03-005442 · edgar.xml · derivative · entry 8 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 20,000 shares Expires 2004-04-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2003 Filed Aug 12, 2003 20:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 7,500 | $63.15 | $473,625.00 |
DisclosureSEC source: 0001179110-03-005442 · edgar.xml · nonDerivative · entry 7 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,790 F1 · balance_after: Amount of Securities Beneficially Owned at End of Month (Table 1, Col. 5)includes 716 shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan on 06/30/03. F2 · balance_after: All shares and dollar amounts reflect two-for-one stock splits in February 2001 and March 2002. Read SEC document |
| August 08, 2003 Filed Aug 12, 2003 20:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 22,500 | $62.28 | $1,401,300.00 |
DisclosureSEC source: 0001179110-03-005442 · edgar.xml · nonDerivative · entry 6 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 318,290 Read SEC document |
| August 08, 2003 Filed Aug 12, 2003 20:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 30,000 | $5.63 | $168,750.00 |
DisclosureSEC source: 0001179110-03-005442 · edgar.xml · nonDerivative · entry 5 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2003 Filed Aug 12, 2003 20:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 5,000 | $63.15 | $315,750.00 |
DisclosureSEC source: 0001179110-03-005442 · edgar.xml · nonDerivative · entry 4 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 310,790 Read SEC document |
| August 08, 2003 Filed Aug 12, 2003 20:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 2,000 | $63.20 | $126,400.00 |
DisclosureSEC source: 0001179110-03-005442 · edgar.xml · nonDerivative · entry 3 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 315,790 Read SEC document |
| August 08, 2003 Filed Aug 12, 2003 20:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | SaleCommon Stock | 13,000 | $63.00 | $819,000.00 |
DisclosureSEC source: 0001179110-03-005442 · edgar.xml · nonDerivative · entry 2 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 317,790 Read SEC document |
| August 08, 2003 Filed Aug 12, 2003 20:53 UTC | GILEAD SCIENCES, INC. GILD · Entity 405 | Exercise / conversionCommon Stock | 20,000 | $3.50 | $70,000.00 |
DisclosureSEC source: 0001179110-03-005442 · edgar.xml · nonDerivative · entry 1 MARTIN JOHN C · CIK 0001190578 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,790 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.